NCT01497444View on ClinicalTrials.gov

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

November 1, 2019

Conditions
Kidney CancerLiver Cancer
Interventions
DRUG

hypoxia-activated prodrug TH-302

DRUG

sorafenib tosylate

Trial Locations (2)

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Collaborators (1)

Threshold Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Threshold Pharmaceuticals

INDUSTRY

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT01497444 - Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter